Background and aims: The widespread use of anti-tumour necrosis factor a antibody (Infliximab) in Crohn's disease (CD) raises concerns about a possible cancer risk in the long term. In a matched pair study, we assessed whether Infliximab is associated with an increased risk of neoplasia. Methods: In a multicentre matched pair study, 404 CD patients treated with Infliximab (CD-IFX) were matched with 404 CD patients who had never received Infliximab (CD-C). Cases and controls were matched for sex, age (+/- 5 years), site of CD, age at diagnosis (+/- 5 years), immunosuppressant use, and follow up. New diagnoses of neoplasia from April 1999 to October 2004 were recorded. Results: Among the 404 CD-IFX, neoplasia was diagnosed in nine patients (2.22%) while among the 404 CD-C, seven patients developed neoplasia (1.73%) (odds ratio 1.33 (95% confidence interval 0.46 - 3.84); p = 0.40). The survival curve adjusted for patient year of follow up showed no differences between CD-IFX and CD-C (p = 0.90; log rank test). In the CD-IFX group, there was one cholangiocarcinoma, three breast cancers, one skin cancer, one leukaemia, one laryngeal cancer, and two anal carcinomas. Among the 7/404 (1.73%) CD-C, there were three intestinal adenocarcinomas (two caecum, one rectum), one basalioma, one spinalioma, one non-Hodgkin's lymphoma, and one breast cancer. Age at diagnosis of neoplasia did not differ between groups (CD-IFX v CD-C: median 50 (range 40 - 70 years) v 45 (27 - 72); p = 0.50). Conclusion: In our multicentre matched pair study, the frequency of a new diagnosis of neoplasia in CD patients treated with Infliximab was comparable with CD patients who had never received Infliximab.

Biancone, L., Orlando, A., Kohn, A., Colombo, E., Sostegni, R., Angelucci, E., et al. (2006). Infliximab and newly diagnosed neoplasia in Crohn's disease: A multicentre matched pair study. GUT, 55(2), 228-233 [10.1136/gut.2005.075937].

Infliximab and newly diagnosed neoplasia in Crohn's disease: A multicentre matched pair study

BIANCONE, LIVIA;PALLONE, FRANCESCO
2006-01-01

Abstract

Background and aims: The widespread use of anti-tumour necrosis factor a antibody (Infliximab) in Crohn's disease (CD) raises concerns about a possible cancer risk in the long term. In a matched pair study, we assessed whether Infliximab is associated with an increased risk of neoplasia. Methods: In a multicentre matched pair study, 404 CD patients treated with Infliximab (CD-IFX) were matched with 404 CD patients who had never received Infliximab (CD-C). Cases and controls were matched for sex, age (+/- 5 years), site of CD, age at diagnosis (+/- 5 years), immunosuppressant use, and follow up. New diagnoses of neoplasia from April 1999 to October 2004 were recorded. Results: Among the 404 CD-IFX, neoplasia was diagnosed in nine patients (2.22%) while among the 404 CD-C, seven patients developed neoplasia (1.73%) (odds ratio 1.33 (95% confidence interval 0.46 - 3.84); p = 0.40). The survival curve adjusted for patient year of follow up showed no differences between CD-IFX and CD-C (p = 0.90; log rank test). In the CD-IFX group, there was one cholangiocarcinoma, three breast cancers, one skin cancer, one leukaemia, one laryngeal cancer, and two anal carcinomas. Among the 7/404 (1.73%) CD-C, there were three intestinal adenocarcinomas (two caecum, one rectum), one basalioma, one spinalioma, one non-Hodgkin's lymphoma, and one breast cancer. Age at diagnosis of neoplasia did not differ between groups (CD-IFX v CD-C: median 50 (range 40 - 70 years) v 45 (27 - 72); p = 0.50). Conclusion: In our multicentre matched pair study, the frequency of a new diagnosis of neoplasia in CD patients treated with Infliximab was comparable with CD patients who had never received Infliximab.
Pubblicato
Rilevanza internazionale
Articolo
Sì, ma tipo non specificato
Settore MED/12 - Gastroenterologia
English
azathioprine; ciprofloxacin; infliximab; mercaptopurine; mesalazine; metronidazole; steroid; adolescent; adult; aged; anus cancer; article; basal cell carcinoma; bile duct carcinoma; breast cancer; cancer; cancer diagnosis; cancer risk; cancer survival; carcinogenesis; child; Crohn disease; disease association; female; human; larynx cancer; leukemia; major clinical study; male; nonhodgkin lymphoma; priority journal; skin cancer; spinal cord cancer; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Child; Crohn Disease; Epidemiologic Methods; Female; Gastrointestinal Agents; Humans; Male; Middle Aged; Neoplasms; Smoking; Tumor Necrosis Factor-alpha
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1856527/pdf/228.pdf
Biancone, L., Orlando, A., Kohn, A., Colombo, E., Sostegni, R., Angelucci, E., et al. (2006). Infliximab and newly diagnosed neoplasia in Crohn's disease: A multicentre matched pair study. GUT, 55(2), 228-233 [10.1136/gut.2005.075937].
Biancone, L; Orlando, A; Kohn, A; Colombo, E; Sostegni, R; Angelucci, E; Rizzello, F; Castiglione, F; Benazzato, L; Papi, C; Meucci, G; Riegler, G; Petruzziello, ; C. Mocciaro, F; Geremia, A; Calabrese, E; Cottone, M; Pallone, F
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
Infliximab and newly diagnosed neoplasia.pdf

accesso aperto

Licenza: Creative commons
Dimensione 485.88 kB
Formato Adobe PDF
485.88 kB Adobe PDF Visualizza/Apri

Questo articolo è pubblicato sotto una Licenza Licenza Creative Commons Creative Commons

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/28826
Citazioni
  • ???jsp.display-item.citation.pmc??? 29
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 112
social impact